Date of Report (Date of earliest event reported): January 29, 2003
BioMarin
Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 000-26727 | 68-0397820 | |||
| (State or other jurisdiction of incorporation or organization | (Commission File Number) | (IRS Employer Identification No.) | |||
| 371 Bel Marin Keys Blvd., Suite 210, Novato, California | 94949 | ||
| (Address of principal executive offices) | (Zip Code) | ||
Not Applicable
(Former
name or former address, if changed since last report)
On January 29, 2003, BioMarin Pharmaceutical Inc. (the “Registrant”) issued a press release regarding its receipt of a complete response letter from the U.S. Food and Drug Administration related to the marketing application for Aldurazyme. The Registrant's press release issued on January 29, 2003 is attached hereto as Exhibit 99.1.
(a) Financial Statements of Business Acquired.
Not Applicable.
(b) Pro Forma Financial Information.
Not Applicable.
(c) Exhibits.
Exhibit 99.1 Press Release of the Registrant dated January 29, 2003.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BioMarin Pharmaceutical Inc., | ||
| a Delaware corporation |
| Date: January 29, 2003 |
By: /s/ Louis Drapeau | |
| Louis Drapeau | ||
| Chief Financial Officer |
| Exhibit No. | Description | ||
| Exhibit 99.1 | Press Release of the Registrant dated January 29, 2003 | ||